PacBio Reports Q4 2025 Revenue Of ~$44.6M; FY25 Revenue Of ~$160M
Benzinga Newsdesk 9 months ago
NewsGuidance
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively.
"We finished the year with strong momentum driven by increased Revio and Vega sales as well as record consumables revenue, reflecting meaningful traction across a range of clinical sequencing applications," said Christian Henry, President and CEO of PacBio. "In 2025, we also significantly reduced our cash burn and strengthened our financial profile. Looking ahead, we believe that increased real-world evidence in the clinic, combined with the significantly lower costs enabled by SPRQ-Nx, will catalyze our next phase of growth in 2026 and beyond."
Fourth quarter and full year results:
| Q4 2025 (Preliminary, unaudited) | Q4 2024 | 2025 (Preliminary, unaudited) | 2024 | |
| Revenue (in millions) | ~$44.6 | $39.2 | ~$160.0 | $154.0 |
| Instrument revenue (in millions) | ~$17.3 | $15.3 | ~$53.8 | $65.8 |
| Consumable revenue (in millions) | ~$21.6 | $18.8 | ~$81.9 | $70.3 |
| Service and other revenue (in millions) | ~$5.7 | $5.1 | ~$24.3 | $17.9 |
| RevioTM system placements | 21 | 23 | 61 | 97 |
| VegaTM system placements | 42 | 7 | 140 | 7 |
| Annualized Revio pull-through per system | ~$242,000 | ~$240,000 | ||
| Ending cash, cash equivalents, and investments (in millions) | ~$279.5 | $389.9 |